Literature DB >> 7783535

Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group.

E Bayerdörffer1, A Neubauer, B Rudolph, C Thiede, N Lehn, S Eidt, M Stolte.   

Abstract

Lymphoma of gastric-mucosa-associated lymphatic tissue (MALT) type has been linked to infection with Helicobacter pylori. We investigated the effect on MALT lymphoma of eradicating H pylori infection. 33 patients with primary gastric low-grade MALT lymphoma associated with H pylori gastritis were treated with omeprazole (120 mg daily) and amoxycillin (2.25 g daily) for 14 days to eradicate H pylori. In addition to histology, PCR was used to examine proliferation of monoclonal B cells before treatment and during follow-up. All patients had at least two post-treatment examinations, and all became negative for H pylori, 2 after a second treatment course. On histology, 23 (70%) patients showed complete regression and 4 (12%) partial regression of lymphoma. 6 (18%) patients had no change after cure of H pylori infection. 1 was treated with chemotherapy. Of 5 treated surgically, 4 were found to have high-grade B-cell lymphoma on histology of the resected stomach and 1 a high-grade T-cell lymphoma. PCR showed complete disappearance of monoclonal B cells after cure of H pylori infection in 13 of 16 patients investigated. During median follow-up of 1 year no relapse of MALT lymphoma occurred. Low-grade primary gastric MALT lymphoma can completely regress after eradication of H pylori infection. However, longer follow-up is needed to clarify whether the remission is lasting.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7783535     DOI: 10.1016/s0140-6736(95)90113-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  166 in total

1.  Seroepidemiology of Helicobacter pylori infection among asymptomatic Chinese children.

Authors:  Chun-Di Xu; Shun-Nian Chen; Shi-Hu Jiang; Jia-Yu Xu
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

2.  Dyspepsia, peptic ulcer disease, and esophageal reflux disease.

Authors:  Mark D Schwartz
Journal:  West J Med       Date:  2002-03

3.  Diagnosis, treatment decisions, and follow up in primary gastric lymphoma.

Authors:  H Boot; D de Jong
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

4.  Blood groups Lewis(b) and ABH expression in gastric mucosa: lack of inter-relation with Helicobacter pylori colonisation and occurrence of gastric MALT lymphoma.

Authors:  G Oberhuber; A Kranz; C Dejaco; B Dragosics; I Mosberger; W Mayr; T Radaszkiewicz
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

5.  Low-grade B cell lymphomas of mucosa-associated lymphoid tissue (MALT-type) require CD40-mediated signaling and Th2-type cytokines for in vitro growth and differentiation.

Authors:  A Greiner; C Knörr; Y Qin; W Sebald; A Schimpl; J Banchereau; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

6.  MALT Lymphoma of the Gastric Remnant After Roux-en-Y Gastric Bypass.

Authors:  Ahmed Jawad; Allan H Bar; Demetri Merianos; Jing Zhou
Journal:  J Gastrointest Cancer       Date:  2012-09

7.  Efficacy of rituximab in gastric diffuse large B cell lymphoma patients.

Authors:  Davide Leopardo; Giuseppe Di Lorenzo; Amalia De Renzo; Piera Federico; Serena Luponio; Carlo Buonerba; Elide Matano; Gerardina Merola; Martina Imbimbo; Enzo Montesarchio; Antonio Rea; Maria-Carmela Merola; Sabino De Placido; Giovannella Palmieri
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

8.  Primary duodenal mucosa-associated lymphoid tissue (MALT) lymphoma--a rare presentation of gastric outlet obstruction.

Authors:  Tamar Tadmor; Tova Rainis; Jacob Bejar; Dina Attias; Alexandra Lavy
Journal:  Can J Gastroenterol       Date:  2007-06       Impact factor: 3.522

9.  Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series.

Authors:  W Fischbach; M-E Goebeler-Kolve; B Dragosics; A Greiner; M Stolte
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

10.  Do we eradicate Helicobacter pylori in hospitalized patients with peptic ulcer disease?

Authors:  Frank Wong; George Ou; Sigrid Svarta; Ricky Kwok; Kieran Donaldson; Joe Frenette; Robert Enns
Journal:  Can J Gastroenterol       Date:  2013-09-13       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.